Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model

Detalhes bibliográficos
Autor(a) principal: Dowdy, David W.
Data de Publicação: 2014
Outros Autores: Golub, Jonathan E., Saraceni, Valeria, Moulton, Lawrence H., Cavalcante, Solange C., Cohn, Silvia, Pacheco, Antonio G., Chaisson, Richard E., Durovni, Betina
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/35394
Resumo: Solange C. Cavalcante. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento.
id CRUZ_ddd39e1ab29937418d9684177fde12ab
oai_identifier_str oai:www.arca.fiocruz.br:icict/35394
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Dowdy, David W.Golub, Jonathan E.Saraceni, ValeriaMoulton, Lawrence H.Cavalcante, Solange C.Cohn, SilviaPacheco, Antonio G.Chaisson, Richard E.Durovni, Betina2019-09-09T12:53:25Z2019-09-09T12:53:25Z2014DOWDY, David W. et al. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. Journal of Acquired Immune Deficiency Syndromes, v. 66, n. 5, p. 1-16, 2014.1525-4135https://www.arca.fiocruz.br/handle/icict/3539410.1097/QAI.00000000000002191944-7884Solange C. Cavalcante. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento.2020-09-09Johns Hopkins University. School of Medicine. Center for Tuberculosis Research. Baltimore, MA, USA / Johns Hopkins University. Johns Hopkins Bloomberg School of Public Health. Department of Epidemiology. Baltimore, MA, USA.Johns Hopkins University. School of Medicine. Center for Tuberculosis Research. Baltimore, MA, USA / Johns Hopkins University. Johns Hopkins Bloomberg School of Public Health. Department of Epidemiology. Baltimore, MA, USA.Municipal Health Secretariat. Rio de Janeiro, RJ, Brazil.Johns Hopkins University. Johns Hopkins Bloomberg School of Public Health. Department of International Health. Baltimore, MA, USA.Municipal Health Secretariat. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Johns Hopkins University. School of Medicine. Center for Tuberculosis Research. Baltimore, MA, USAFundação Oswaldo Cruz. Presidência. Programa de Computação Científica. Rio de Janeiro, RJ, Brasil.Johns Hopkins University. School of Medicine. Center for Tuberculosis Research. Baltimore, MA, USA / Johns Hopkins University. Johns Hopkins Bloomberg School of Public Health. Department of Epidemiology. Baltimore, MA, USA / Johns Hopkins University. Johns Hopkins Bloomberg School of Public Health. Department of International Health. Baltimore, MA, USA.Municipal Health Secretariat. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.Background —The potential epidemiological impact of isoniazid preventive therapy (IPT), delivered at levels that could be feasibly scaled up among people living with HIV (PLHIV) in modern, moderate-burden settings, remains uncertain. Methods — We used routine surveillance and implementation data from a cluster-randomized trial of IPT among HIV-infected clinic patients with good access to antiretroviral therapy in Rio de Janeiro, Brazil, to populate a parsimonious transmission model of TB/HIV. We modeled IPT delivery as a constant process capturing a proportion of the eligible population every year. We projected feasible reductions in tuberculosis (TB) incidence and mortality in the general population and among PLHIV specifically at the end of five years after implementing an IPT program. Results — Data on time to IPT fit an exponential curve well, suggesting that IPT was delivered at a rate covering 20% (95% confidence interval: 16%, 24%) of the 2,500 eligible individuals each year. By the end of year 5 after modeled program roll-out, IPT had reduced TB incidence by 3.0% (95% uncertainty range, UR: 1.6%, 7.2%) in the general population and by 15.6% (95%UR: 15.5%, 36.5%) among PLHIV. Corresponding reductions in TB mortality were 4.0% (95%UR: 2.2%, 10.3%) and 14.3% (14.6%, 33.7%). Results were robust to wide variations in parameter values on sensitivity analysis. Conclusions — TB screening and IPT delivery can substantially reduce TB incidence and mortality among PLHIV in urban, moderate-burden settings. In such settings, IPT can be an important component of a multi-faceted strategy to feasibly reduce the burden of TB in PLHIV.engLippincott, Williams & WilkinsImpact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological modelinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleTuberculosisInfectious disease transmissionHIVTheoretical modelsBrazilIsoniazidinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/35394/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALva_Dowdy_David_etal__INI_2014.pdfva_Dowdy_David_etal__INI_2014.pdfapplication/pdf896069https://www.arca.fiocruz.br/bitstream/icict/35394/2/va_Dowdy_David_etal__INI_2014.pdf205b6a22880a1bc728fb58efcdbd1e42MD52TEXTva_Dowdy_David_etal__INI_2014.pdf.txtva_Dowdy_David_etal__INI_2014.pdf.txtExtracted texttext/plain43359https://www.arca.fiocruz.br/bitstream/icict/35394/3/va_Dowdy_David_etal__INI_2014.pdf.txtcaadb7cabcf0e10e8a3e01ef4026dc15MD53icict/353942021-03-24 16:32:36.213oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-03-24T19:32:36Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model
title Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model
spellingShingle Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model
Dowdy, David W.
Tuberculosis
Infectious disease transmission
HIV
Theoretical models
Brazil
Isoniazid
title_short Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model
title_full Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model
title_fullStr Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model
title_full_unstemmed Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model
title_sort Impact of isoniazid preventive therapy for HIV-infected adults in rio de Janeiro, Brazil: an epidemiological model
author Dowdy, David W.
author_facet Dowdy, David W.
Golub, Jonathan E.
Saraceni, Valeria
Moulton, Lawrence H.
Cavalcante, Solange C.
Cohn, Silvia
Pacheco, Antonio G.
Chaisson, Richard E.
Durovni, Betina
author_role author
author2 Golub, Jonathan E.
Saraceni, Valeria
Moulton, Lawrence H.
Cavalcante, Solange C.
Cohn, Silvia
Pacheco, Antonio G.
Chaisson, Richard E.
Durovni, Betina
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Dowdy, David W.
Golub, Jonathan E.
Saraceni, Valeria
Moulton, Lawrence H.
Cavalcante, Solange C.
Cohn, Silvia
Pacheco, Antonio G.
Chaisson, Richard E.
Durovni, Betina
dc.subject.en.pt_BR.fl_str_mv Tuberculosis
Infectious disease transmission
HIV
Theoretical models
Brazil
Isoniazid
topic Tuberculosis
Infectious disease transmission
HIV
Theoretical models
Brazil
Isoniazid
description Solange C. Cavalcante. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento.
publishDate 2014
dc.date.issued.fl_str_mv 2014
dc.date.accessioned.fl_str_mv 2019-09-09T12:53:25Z
dc.date.available.fl_str_mv 2019-09-09T12:53:25Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv DOWDY, David W. et al. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. Journal of Acquired Immune Deficiency Syndromes, v. 66, n. 5, p. 1-16, 2014.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/35394
dc.identifier.issn.pt_BR.fl_str_mv 1525-4135
dc.identifier.doi.none.fl_str_mv 10.1097/QAI.0000000000000219
dc.identifier.eissn.none.fl_str_mv 1944-7884
identifier_str_mv DOWDY, David W. et al. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. Journal of Acquired Immune Deficiency Syndromes, v. 66, n. 5, p. 1-16, 2014.
1525-4135
10.1097/QAI.0000000000000219
1944-7884
url https://www.arca.fiocruz.br/handle/icict/35394
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Lippincott, Williams & Wilkins
publisher.none.fl_str_mv Lippincott, Williams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/35394/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/35394/2/va_Dowdy_David_etal__INI_2014.pdf
https://www.arca.fiocruz.br/bitstream/icict/35394/3/va_Dowdy_David_etal__INI_2014.pdf.txt
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
205b6a22880a1bc728fb58efcdbd1e42
caadb7cabcf0e10e8a3e01ef4026dc15
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798325046541811712

Registros relacionados